Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a ...

Compounded Ozempic and Wegovy, cheaper generic versions of the weight-loss drugs, can no longer be sold. Doctor explains ...

Semaglutide, the active ingredient in popular drugs Ozempic and Wegovy, isn’t without its risks. A recent study has found ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Last week, Pfizer announced that it would no longer develop danuglipron, a daily GLP-1 weight-loss drug which investors were ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

Blue Cross Blue Shield of Massachusetts says it will soon stop covering popular drugs for weight loss, like Ozempic and ...